Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Roche partners with Tekmira Pharmaceuticals to advance RNAi
June 2009
SHARING OPTIONS:

VANCOUVER, British Columbia—Roche and Tekmira Pharmaceuticals Corp. announced in May that they have entered into a product development agreement to advance Roche's first two RNAi product candidates into human clinical testing. Both of the product candidates will be based on Tekmira's stable nucleic acid–lipid particle technology. Under the terms of the agreement, Roche will pay Tekmira up to $18.4 million to support the advancement of the product candidates to the filing of Investigational New Drug (IND) applications. Tekmira is also eligible to receive up to $32 million in milestones plus royalties on product sales as the first two products are advanced through development and commercialization based on Roche's access to Tekmira's intellectual property under previously announced agreements. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.